Clinical trials: Advanced Cirrhosis
Advanced Chronic Liver Disease, Healthy Participants
A Study to Investigate the Pharmacokinetics of AZD2389 in Healthy Participants When Administered Alone and in Combination With Quinidine
The purpose of this study is to assess the pharmacokinetics (PK) and safety of AZD2389 when administered alone and in combination with quinidine in healthy participants.
- Trial name
- NCT06974565
- Testing
- AZD2389, Quinidine
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Cirrhosis
MASLD in Type 2 Diabetes in Primary Care - a Follow-up Study
The goal of this observational study is to understand how metabolic dysfunction-associated steatotic liver disease (MASLD) changes over time in individuals with type 2 diabetes who previously participated in the EPSONIP study.
- Conditions
- MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Cirrhosis, Advanced Fibrosis, Sarcopenia
- Trial name
- EPSOMIP2 (NCT07312136)
- Where
- Sweden
- Volunteers
- 317 people
- Sponsor
- Linkoeping University
Alcoholic Liver Disease, Alcoholic Fibrosis of Liver
Early Detection of Alcoholic Liver Disease
This is an observational study to identify the prevalence of advanced liver fibrosis among patients with excessive alcohol intake using a non-invasive method (FibroScan®) and to characterize the main environmental, genetic and…
- Conditions
- Alcoholic Liver Disease, Alcoholic Fibrosis of Liver, Alcoholic Cirrhosis, Excessive Drinking
- Trial name
- NCT04070508
- Sponsor
- University of Pittsburgh
Non-Alcoholic Fatty Liver Disease, Chronic Liver Disease
Combination Diagnostic Strategies in NAFLD
Serial combination of biological and elastography tests is accurate to diagnosing advanced fibrosis in non-alcoholic fatty liver disease (NAFLD) patients.
- Trial name
- CombinationSSI (NCT04384159)
- Volunteers
- 577 people
- Sponsor
- University Hospital, Montpellier
Non-Alcoholic Fatty Liver Disease
Screening for NAFLD-related Advanced Fibrosis in High Risk Population in Diabetology.
Nonalcoholic fatty liver disease (NAFLD) is being recognized as one of the most prevalent causes of chronic liver disease worldwide.
- Trial name
- NAFLD-CARE (NCT04435054)
- Testing
- Non-invasive blood-based and imaging-based tests for the screening of NAFLD-related advanced fibrosis.
- Where
- 3 sites in France
- Volunteers
- 1,000 people
- Sponsor
- Hospices Civils de Lyon
Steatotic Liver Disease, Fibrosis of Liver
Screening for MASLD-related Advanced Fibrosis in Type 2 Diabetes
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects approximately 25% of the global adult population, 25-30% of whom suffer from metabolic dysfunction-associated steatohepatitis (MASH), increasing the risk of…
- Trial name
- MASLD-DIAB (NCT07270822)
- Testing
- Collaborative care pathways group, Control group without intervention
- Where
- 10 sites in France
- Volunteers
- 1,714 people
- Sponsor
- Hospices Civils de Lyon
Compensated Cirrhosis, Gastroesophageal Varices Bleeding
Detachable String Magnetically Controlled Capsule Endoscopy for Detecting High-risk Varices in Compensated Cirrhosis
Gastroesophageal varices is a serious complication of compensated advanced chronic liver disease (cACLD). Primary prophylaxis to reduce the risk of variceal haemorrhage is recommended if high-risk varices (HRV) are detected.
- Trial name
- NCT03749954
- Testing
- Detachable string magnetically controlled capsule endoscopy
- Where
- 13 sites in China, United Kingdom
- Volunteers
- 105 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Advanced Chronic Liver Disease, Portal Hypertension Related to Cirrhosis
Program to Avoid NSAIDs in Patients With Advanced Chronic Liver Disease
This study aims to implement measures to avoid the use of NSAIDs or metamizole in patients with advanced chronic liver disease (ACLD) scheduled for major surgery, which are contraindicated due to increased risk of renal…
- Trial name
- NCT07249294
- Testing
- Multidisciplinary support program
- Where
- Spain
- Volunteers
- 84 people
- Sponsor
- Parc de Salut Mar
Hepatitis C Virus, Advanced Fibrosis
Study of Long-term Peg Intron vs. Colchicine in Non-responders.
In this study Peg-Intron will be tested to see if it will give better results than Colchicine. At this time, there is currently no recommended maintenance treatment for patients who have failed to respond to…
- Conditions
- Hepatitis C Virus, Advanced Fibrosis, Cirrhosis
- Trial name
- COPILOT (NCT00179413)
- Testing
- PEG -Intron, Colchicine
- Where
- 49 sites in United States
- Volunteers
- 549 people
- Sponsor
- Beth Israel Deaconess Medical Center
Alcoholism, Liver Disease
Transient Elastography in the Determination of Advanced Fibrosis in Alcoholic Liver Disease.
Alcoholic liver disease is the most frequent complication of excessive alcohol consumption. Early diagnosis of alcoholic liver disease is essential to avoid its complications that could be fatal.
- Conditions
- Alcoholism, Liver Disease, Liver Fibrosis
- Trial name
- FIBR-OH (NCT01789008)
- Testing
- Determination of Advanced Fibrosis in Alcoholic Liver Disease
- Where
- France
- Volunteers
- 300 people
- Sponsor
- Rennes University Hospital
Hepatocellular Carcinoma, Cirrhosis
LDE225 in Patients With Advanced or Metastatic Hepatocellular Carcinoma and Child-Pugh A/B7 Cirrhosis
The purpose of this study is to test the safety and determine the maximum safe dose of an experimental drug called LDE225 (hedgehog inhibitor) in people with liver cancer.
- Trial name
- NCT02151864
- Testing
- LDE225
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Jason K. Sicklick, M.D.
HCC, Liver Cirrhosis
Open Label Trial of Immunotherapy for Advanced Liver Cancer
The purpose of this study is to evaluate daily dosing of oral immunotherapy hepcortespenlisimut-L (V5) in patients with advanced stage of HCC not amenable to surgical intervention or with recurrent tumor after surgery.
- Trial name
- HCC (NCT02256514)
- Testing
- Daily oral dose of hepcortespenlisimut-L
- Where
- Mongolia
- Volunteers
- 120 people
- Sponsor
- Immunitor LLC
BCLC Stage C HCC, CP-B Liver Cirrhosis
Sorafenib PK in Patients With Advanced HCC and Child-Pugh B
Sorafenib has proven efficacy in advanced hepatocellular carcinoma (HCC). Most patients with HCC have impaired liver function due to underlying liver cirrhosis.
- Trial name
- SORBE (NCT04051853)
- Testing
- Sorafenib, Midazolam clearance test, CYP cocktail clearance test
- Where
- Netherlands
- Volunteers
- 5 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Chronic Hepatitis C, Cirrhosis
Interferon/Ribavirin-Free Sofosbuvir Based Treatment (AURIC)
Since the availability of interferon free direct acting antivirals (DAA) the centers authorized to prescribed these drugs in Austria submitted their data to a central data base (AURIC) using treatment regimes without interferon…
- Trial name
- AURIC (NCT02628717)
- Where
- Austria
- Volunteers
- 558 people
- Sponsor
- Medical University of Vienna
Cirrhosis, End Stage Liver Disease
Screening for Liver Cancer With CT vs. Ultrasound in Patients With Advanced Liver Disease
The purpose of this study is to determine whether ultrasound or CT scanning is more effective at detecting early liver cancer in patients with advanced liver disease.
- Conditions
- Cirrhosis, End Stage Liver Disease, Hepatitis C
- Trial name
- NCT01350167
- Testing
- Screening
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Minneapolis Veterans Affairs Medical Center
Hepatocellular Carcinoma
The Study of the Validation of General Evaluation Score (GES) in the Prediction of Hepatocellular Carcinoma Risk Among Patients With Advanced Fibrosis and Cirrhosis Who Achieved Sustained Virological Response for Hepatitis C Virus After Direct Acting Antiviral Drugs
This cohort study aims to evaluate the validation of general evaluation score in the prediction of hepatocellular carcinoma risk among patients with advanced fibrosis (F3) and cirrhosis (F4) who achieved sustained virological…
- Trial name
- NCT06325826
- Testing
- General Evaluation Score (GES)
- Where
- Egypt
- Volunteers
- 500 people
- Sponsor
- Egyptian Liver Hospital
Intrahepatic Cholangiocarcinoma (Icc), Cholangiocarcinoma
A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors
This is an open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetic (what the body does to the drug), pharmacodynamic (what the drug does to the body), and antitumor activity of CGT4859 in adult…
- Conditions
- Intrahepatic Cholangiocarcinoma (Icc), Cholangiocarcinoma, Other Solid Tumors, Adult, FGFR2 Gene Fusion/Rearrangement
- Trial name
- NCT06777316
- Testing
- CGT4859
- Where
- 13 sites in United States, Canada
- Volunteers
- 110 people
- Sponsor
- Cogent Biosciences, Inc.
Liver Diseases, Alcoholic, Fibrosis
Screening At-risk Populations for Hepatic Fibrosis With Non-invasive Markers
Prospective screening study at Odense University Hospital to assess the effect of transient elastography and other serum and imaging markers of liver fibrosis to detect advanced fibrosis (Kleiner Fibrosis score F3-F4) in patients…
- Trial name
- SIPHON (NCT03308916)
- Testing
- transient elastography, Enhanced liver fibrosis test, Indirect serum markers of liver fibrosis
- Where
- Denmark
- Volunteers
- 6,500 people
- Sponsor
- Maja Thiele
Intrahepatic Cholangiocarcinoma (Icc)
Adebrelimab Combined with Irinotecan Liposomes, 5-FU, CF ± Lenvatinib As First-line Treatment for Advanced ICC
This is a multicenter, open label, randomized, two-arm clinical study to observe and evaluate the efficacy and safety of adebrelimab combined with irinotecan liposomes, 5-fluorouracil, calcium folinate ± lenvatinib as first-line…
- Trial name
- NCT06648525
- Testing
- Adebrelimab, Irinotecan liposomes, Lenvatinib
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Harbin Medical University
Metabolic Dysfunction-Associated Steatotic Liver Disease, Liver Fibrosis
Automated Passive Case-Finding for Advanced Liver Fibrosis in MASLD: The LiverSeek Programme
LiverSeek is a fully automated, passive case-finding programme for advanced liver fibrosis associated with metabolic dysfunction-associated steatotic liver disease (MASLD) in primary care.
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease, Liver Fibrosis, Non-alcoholic Fatty Liver Disease NAFLD, Type 2 Diabetes Mellitus
- Trial name
- LiverSeek (NCT07658755)
- Where
- Spain
- Volunteers
- 3,000 people
- Sponsor
- Hospital General Universitario Gregorio Marañon